Objective: This research is using a cross-sectional study with a total of subjects consisted of 88 patients in The General Hospital of Dr. Soedirman Kebumen from January 2020 until December 2020. Subjects were male and female, aged 17-80 years old who only had a primer diagnosis of chronic kidney disease and had completed medical record data. The data taken were the stage of chronic kidney disease (CKD I, CKD II, CKD III, CKD IV, and CKD V) that is based on WHO diagnostic criteria and the patient's liver enzyme (Serum glutamic oxaloacetic transaminase/SGOT and serum glutamic pyruvic transaminase/SGPT). The data obtained then analyzed using statistical analysis software. Methods: There are 32 patients with CKD I and the mean of SGOT/SGPT (U/L) was 24±1.6/18.8±2.9. There are 16 patients with CKD II and the mean of SGOT/SGPT (U/L) was 21.75±8.83/21.258±11.67. There are 16 patients with CKD III and the mean of SGOT/SGPT (U/L) was 83±16.34/41.258±11.38. There are 12 patients with CKD IV and the mean of SGOT/SGPT (U/L) was 61±15.04/113±56.50. There are 12 patients with CKD V and the mean of SGOT/SGPT (U/L) was 351.33±18.98/114±47.12. The result of statistical analysis showed there was a relationship between CKD and liver function (SGOT and SGPT) with p-value < 0.001.              Results: There is a relationship between CKD stage and liver function that sign by increasing the level of liver enzyme (SGOT/SGPT) with p-value < 0.001.     Conclusions: Objective: Chronic kidney disease can lead to hypoxia condition and an increase of oxidative stress in the body. This condition can stimulate liver injury. The previous research showed there is a relationship between kidney disease and liver injury called a hepatorenal syndrome. This research aims to know the relationship between Chronic Kidney Disease Stage and Liver Function in Chronic Kidney Disease Patients at The General Hospital of Dr. Soedirman Kebumen, Central, Java, Indonesia. Methods: This research is using a cross-sectional study with a total of subjects consisted of 88 patients in The General Hospital of Dr. Soedirman Kebumen from January 2020 until December 2020. Subjects were male and female, aged 17-80 years old who only had a primer diagnosis of chronic kidney disease and had completed medical record data. The data taken were the stage of chronic kidney disease (CKD I, CKD II, CKD III, CKD IV, and CKD V) that is based on WHO diagnostic criteria and the patient's liver enzyme (Serum glutamic oxaloacetic transaminase/SGOT and serum glutamic pyruvic transaminase/SGPT). The data obtained then analyzed using statistical analysis software. Results: There are 32 patients with CKD I and the mean of SGOT/SGPT (U/L) was 24±1.6/18.8±2.9. There are 16 patients with CKD II and the mean of SGOT/SGPT (U/L) was 21.75±8.83/21.258±11.67. There are 16 patients with CKD III and the mean of SGOT/SGPT (U/L) was 83±16.34/41.258±11.38. There are 12 patients with CKD IV and the mean of SGOT/SGPT (U/L) was 61±15.04/113±56.50. There are 12 patients with CKD V and the mean of SGOT/SGPT (U/L) was 351.33±18.98/114±47.12. The result of statistical analysis showed there was a relationship between CKD and liver function (SGOT and SGPT) with p-value < 0.001.              Conclusions: There is a relationship between CKD stage and liver function that sign by increasing the level of liver enzyme (SGOT/SGPT) with p-value < 0.001.